Senior Bioprocess Engineer II, MSAT Proteins Hybrid Equity

Vaxcyte; Indiana (PA); Hybrid; USD 220,000 - 294,000; Full time

Benefits offered by this job

Equity component

Comprehensive benefits

Job summary

Vaxcyte is seeking a Protein Intermediates Sr Bioprocess Engineer to join the Manufacturing Science and Technology (MSAT) team supporting microbial manufacturing from clinical readiness through PPQ and ongoing production. Position based primarily in Visp, Switzerland, with oversight of CMOs in Italy and Germany.

The candidate will manage complex microbial processes, drive process improvements, and lead tech transfers, investigations, CAPAs, and regulatory documentation for the PCV portfolio.

Qualifications

• PhD or Master’s degree with extensive pharma/biotech experience.
• Strong background in GMP drug substance manufacturing.
• Experience with bacterial fermentation, purification, and process analytics.

Responsibilities

• Manage microbial manufacturing processes for vaccine intermediates.
• Oversee CMOs to ensure commercial readiness and process validation.
• Lead investigations, CAPAs, and late-stage process characterization.
• Support technology transfer, equipment qualification, and DOE improvements.
• Author technical/regulatory documents and present to stakeholders.

Skills

Fluency in English

Cross-functional collaboration

Project management

Analytical skills

Process engineering

Education

PhD in Bio/Chemical Engineering or Microbiology/Chemistry/Biochemistry

Master’s degree in Bio/Chemical Engineering or Microbiology/Chemistry/Biochemistry

Job description

Vaxcyte is seeking a Protein Intermediates Sr Bioprocess Engineer to join the Manufacturing Science and Technology (MSAT) team supporting microbial manufacturing from clinical readiness through PPQ and ongoing production. Position based primarily in Visp, Switzerland, with oversight of CMOs in Italy and Germany.

The candidate will manage complex microbial processes, drive process improvements, and lead tech transfers, investigations, CAPAs, and regulatory documentation for the PCV portfolio.